Diurnal Group Plc Successful DITEST Phase I trial outcome

Diurnal (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products, Alkindi and Chronocort, are in late-stage clinical trials, with Alkindi already licensed in Europe. With the successful outcome of the Phase I trial with DITEST, an oral testosterone replacement formulation, DNL is building on its vision of becoming a leading speciality endocrinology company. The study showed that DITEST was safe, well tolerated and well absorbed in men affected by hypogonadism. DNL will engage with the regulators for the next trial stage, which is likely to be run with a partner.

  • Strategy: DNL’s goal is to create a valuable ‘Adrenal Franchise’ that can treat patients with chronic cortisol deficiency diseases from birth and for the rest of their lives. The long-term aim, once Alkindi and Chronocort are established in Europe and the US, is to grow the product offering to other endocrine conditions.
  • Trial outcome: DNL met both primary and secondary endpoints in the Phase I proof-of-concept trial with its testosterone replacement product, DITEST. The product has been shown to be safe, well tolerated, and potentially superior to current oral treatments; this was demonstrated in both fed and fasted states.
  • Market need: Despite a number of testosterone products available in the market, there is still a strong unmet medical need for an oral medication that would allow safe and better compliance for the patient. DITEST will be an added-value product in the $4.8bn testosterone replacement market.
  • Risks: Concerns about the US prospects for Chronocort have been allayed by the positive EMA Scientific Advice and the opportunity to revise its US Phase III protocol. However, this has added extra time to the US development process, delaying the point at which DNL should become cashflow-positive.
  • Investment summary: Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses, due possibly to the need for more capital during 2020.

DOWNLOAD THE FULL REPORT

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Diurnal Group: All set for three pivotal trials

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its drugs target conditions where medical need is currently unmet, with the aim of becoming a global endocrine leader.

    Hardman & Co

    Diurnal Group: And then there were three

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group: Closely watching the regulators

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group Flow of regulatory approvals

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group … and more to come (news flow)

    Diurnal Group PLC (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building

    Hardman & Co

    Diurnal Group Approaching a number of near-term milestones

    Diurnal (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Plc Clarity for Chronocort regulatory pathway

    Diurnal Group Plc (LON: DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of

    Hardman & Co

    Diurnal Group Chronocort – seeking regulatory advice

    Diurnal Group (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Unexpected Phase III trial outcome

    Diurnal Group (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Alkindi®: On route to Europe

    Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical need, with the aim of building

    Hardman & Co

    Diurnal Group Plc Ready to press the button

    Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical need, with the aim of building